The Source • Spring 2019 – Issue 136

In this issue you’ll find a message from Executive Director Karuna Jaggar, our report-back from the 2018 San Antonio Breast Cancer Symposium, what we think about the U.S. Food and Drug Administration’s recent approval of the first immunotherapy drug for breast cancer, and much more. Want The Source delivered directly to your inbox? Sign up here. To print a PDF of this issue, click here.

From the Executive Director: Conflict Free, So We Can Tell the Truth

By the time I came to Breast Cancer Action in 2011, I knew the necessity of unbiased, balanced, accessible information—and I knew how hard it can be to find. I also knew that when you’re choosing between what can feel like a host of bad options when it comes to breast cancer treatments, there really is no single “right” answer. Read More

First Immunotherapy Approval for Breast Cancer Doesn’t Mark a Win for Patients

The U.S. Food and Drug Administration (FDA)’s recent approval of the first immunotherapy drug for breast cancer has been hailed as “exciting” and “revolutionary” by some in the medical field. At Breast Cancer Action, we’re less impressed. Read More

Before You Walk for Breast Cancer

Every spring, breast cancer industry giants like Komen kick off their annual fundraising walks and runs. Here are 4 questions to ask before you participate or donate to one. Read More